background
aim
mesenchym
stromal
cell
msc
ideal
candid
regen
immunomodulatori
therapi
use
xenogen
proteinefre
good
manufactur
practiceecompli
growth
media
prerequisit
clinic
msc
isol
expans
human
platelet
lysat
hpl
effici
implement
msc
clinic
manufactur
substitut
fetal
bovin
serum
fb
use
humanderiv
blood
materi
allevi
immunolog
risk
transmiss
bloodborn
virus
aim
studi
test
even
safer
altern
hpl
fb
hpl
subject
pathogen
inactiv
psoralen
ihpl
method
bone
marrow
sampl
plate
expand
aminimum
essenti
medium
three
cultur
supplement
hpl
ihpl
fb
time
msc
morpholog
growth
immunophenotyp
analyz
passag
karyotyp
tumorigen
steril
analyz
third
passag
statist
analys
perform
result
msc
cultiv
three
differ
cultur
condit
show
signific
differ
term
fibroblast
colonyform
unit
number
immunophenotyp
multipot
capac
convers
hplihplmsc
smaller
numer
higher
prolif
potenti
show
higher
nanog
protein
express
fbsmsc
although
hpl
ihplmsc
exhibit
characterist
may
attribut
higher
primit
stem
fbsmsc
tumorigen
mutat
karyotyp
modif
observ
conclus
demonstr
ihpl
safer
hpl
repres
good
good
manufactur
practiceecompli
altern
fb
msc
clinic
product
even
advantag
term
cellular
growth
stem
rapid
progress
field
biotechnolog
medicin
led
develop
new
treatment
innov
medicin
product
among
latter
new
cellbas
medicin
product
contain
viabl
human
cell
autolog
allogen
origin
high
potenti
cellbas
therapi
variou
sever
diseas
particular
mesenchym
stromal
cell
msc
easili
isol
bone
marrow
bm
thank
capac
adher
prolifer
expand
cultur
msc
multipot
stem
cell
high
immunomodul
proprieti
produc
multipl
cytokin
growth
factor
adhes
molecul
import
factor
influenc
hematopoiet
microenviron
cell
particular
characterist
high
plastic
make
relev
field
cell
therapi
tissu
repair
tissu
engin
strategi
therapeut
product
tailor
number
clinic
scenario
degen
posttraumat
diseas
caus
damag
cell
loss
increas
use
msc
advanc
therapi
medicin
product
atmp
led
product
process
need
meet
good
manufactur
practic
gmp
regulatori
context
advanc
therapi
medicin
product
set
regul
ec
n
design
facilit
patient
access
product
guarante
highest
level
safeti
patient
ensur
product
safeti
efficaci
gmp
guarante
product
consist
produc
control
qualiti
standard
requir
intend
use
collect
releas
includ
cell
harvest
cell
manipul
process
maximum
number
cell
passag
combin
compon
product
fill
packag
forth
although
human
msc
highli
immunogen
expand
xenogen
sera
fetal
bovin
serum
fb
like
gener
immun
respons
patient
administr
shown
singl
prepar
human
msc
grown
standard
condit
fb
carri
approxim
mg
fb
protein
thu
view
clinic
gmp
product
use
xenogen
serum
complic
high
lottolot
variabl
associ
risk
transmit
infecti
agent
immun
effect
therefor
regulatori
guidelin
gmp
product
aim
minim
use
fb
use
expans
protocol
cell
cultur
medium
supplement
reinforc
intens
search
safer
media
supplement
altern
interest
studi
evidenc
possibl
replac
fb
autolog
allogen
platelet
lysat
obtain
singledonor
pool
human
serum
platelet
contain
plethora
growthpromot
factor
moreov
human
platelet
lysat
hpl
establish
safe
effici
msc
cultur
supplement
robust
msc
cultiv
thu
offer
certain
advantag
potenti
fb
substitut
although
use
humanderiv
blood
materi
allevi
immunolog
risk
fb
possibl
transmit
bloodborn
virus
remain
especi
materi
multipl
donor
pool
provid
suffici
volum
therapeuticscal
msc
expans
limit
individu
donor
variabl
pathogen
inactiv
pi
technolog
aim
enhanc
blood
safeti
inactiv
emerg
pathogen
known
yetunidentifi
one
detect
current
screen
test
protocol
sinc
signific
progress
made
pathogen
inactiv
technolog
present
wide
avail
european
blood
servic
multipl
ce
abbrevi
conformit
e
europ
eenn
ie
european
conform
mark
product
treat
platelet
plasma
transfus
ce
mark
state
product
assess
place
market
meet
eu
safeti
health
environment
protect
requir
european
experi
pathogeninactiv
platelet
plasma
number
million
unit
safeti
record
wide
report
literatur
extens
valid
studi
use
blood
product
high
titer
ad
bacteria
envelop
nonenvelop
virus
protozoa
perform
prove
efficaci
therefor
applic
pi
techniqu
platelet
use
prepar
hpl
supplement
cultur
medium
msc
expans
gmp
set
appear
highli
desir
might
obviat
viru
transmiss
problem
present
studi
pi
process
perform
use
intercept
blood
system
technolog
intercept
ceru
europ
bv
amersfoort
netherland
use
photoact
compound
deriv
psoralen
amotosalem
longwavelength
ultraviolet
uva
illumin
exposur
uva
light
amotosalem
becom
reactiv
form
chemic
crosslink
locksup
strand
rna
dna
block
inactiv
replic
virus
bacteria
leukocyt
platelet
concentr
studi
ensur
inactiv
process
induc
chang
cell
set
parallel
msc
cultur
fb
standard
supplement
hpl
recent
use
gmp
condit
cell
growth
supplement
ihpl
batch
hpl
inactiv
compar
effect
three
supplement
cell
growth
immunophenotyp
multipot
capac
karyotyp
tumorigenesi
stem
protein
express
whole
blood
ae
ml
collect
healthi
blood
donor
perform
triplebag
system
freseniu
kabi
bad
homburg
germani
contain
ml
citratephosphatedextros
anticoagul
accord
italian
law
european
guidelin
routin
test
blood
donor
perform
follow
abo
blood
group
irregular
red
blood
cell
antibodi
infecti
marker
hepat
b
c
human
immunodefici
viru
treponema
pallidum
blood
unit
centrifug
separ
plasma
buffi
coat
red
blood
cell
use
autom
blood
compon
separ
compomat
freseniu
kabi
buffi
coateplatelet
concentr
bcpc
prepar
four
ogroup
buffi
coat
pool
abgroup
plasma
centrifug
automat
separ
leukoreduct
filter
use
tacsi
system
terumo
bct
europ
nv
zaventem
belgium
twelv
bcpc
prepar
six
experiment
replic
perform
replic
prepar
two
bcpc
unit
use
pool
split
process
result
six
test
unit
six
pair
control
unit
sampl
taken
unit
evalu
platelet
concentr
platelet
content
leucocyt
contamin
compli
specif
set
transfusion
purpos
use
inactiv
process
set
platelet
concentr
measur
use
hematolog
analyz
sysmex
residu
white
blood
cell
contamin
measur
mean
flow
cytometr
method
bd
leukocount
kit
bd
bioscienc
san
jose
ca
usa
control
unit
remain
untreat
test
unit
steril
dock
intercept
larg
volum
process
set
ceru
corpor
concord
ca
usa
process
accord
manufactur
instruct
compon
treat
j
cm
uva
light
presenc
mmoll
amotosalen
treatment
bcpc
transfer
associ
compound
adsorpt
devic
cad
bag
incub
h
agit
c
sampl
taken
unit
evalu
platelet
concentr
recoveri
inactiv
treatment
steril
bcpc
frozen
c
thaw
c
three
time
obtain
platelet
fragment
growth
factor
releas
bcpc
subsequ
centrifug
min
remov
platelet
bodi
collect
supernat
improv
standard
reduc
individu
donor
variat
six
untreat
supernat
unit
batch
differ
donor
pool
singl
hpl
unit
six
treat
unit
also
pool
batch
hpl
divid
aliquot
ml
frozen
c
use
batch
hpl
ihpl
test
presenc
endogen
adventiti
virus
dna
extract
perform
start
ml
hpl
ihpl
follow
extract
step
use
easi
mag
automat
extractor
biom
erieux
marci
letoil
franc
accord
manufactur
instruct
elut
final
volum
ml
endogen
virus
ml
elut
ad
ml
amplif
mix
bm
cell
harvest
iliac
crest
adult
pediatr
donor
underw
bm
collect
relat
patient
inform
consent
use
part
bm
initi
dedic
transplant
avail
unfilt
bm
collect
bag
baxter
healthcar
corpor
deerfield
il
usa
normal
discard
bm
infus
bag
wash
three
time
phosphatebuff
salin
cell
centrifug
count
plate
directli
differ
cultur
media
first
test
hpl
concentr
iuml
heparin
avoid
coagul
medium
clump
fibrinogen
hpl
find
best
result
term
cellular
growth
elimin
trace
residu
platelet
hpl
filter
filter
use
whole
bm
sampl
equal
split
three
cellular
cultur
condit
aminimum
essenti
medium
amem
sigmaaldrich
lto
irvin
ayrshir
uk
contain
fb
ii
hpl
iii
ihpl
seed
densiti
initi
whole
bm
cellscm
previous
report
day
nonadher
cell
remov
discard
adher
cell
refe
everi
day
reach
confluenc
detach
count
mean
fast
read
dispos
chamber
previous
describ
replat
passag
cellscm
consid
msc
passag
first
time
cell
harvest
replat
cellular
condit
maintain
cellular
plate
whole
bm
expans
process
indic
follow
passag
increas
number
basi
experi
previous
report
data
found
three
passag
suffic
clinic
applic
analyz
cell
quantifi
msc
precursor
perform
colonyform
unit
fibroblast
cfuf
test
bm
cell
plate
directli
amem
contain
fb
hpl
ihpl
densiti
cellscm
cellscm
sixwel
plate
msc
clonogen
precursor
score
macroscop
day
seed
cluster
cell
consid
coloni
experi
perform
duplic
two
differ
oper
cfuf
mean
express
fibroblast
clone
obtain
million
bm
cell
cell
evalu
cellular
growth
cell
growth
rate
express
term
popul
doubl
pd
mean
formula
log
nlog
n
cell
number
detach
cell
divid
initi
number
seed
cell
expans
term
cumul
pd
cpd
analyz
immunophenotyp
flow
cytomet
analysi
perform
adher
cell
passag
briefli
cell
incub
appropri
amount
antibodi
accord
specif
antibodi
titrat
describ
rustichelli
et
al
analyz
stem
protein
express
perform
immonocytochem
stain
homeobox
transcript
factor
nanog
nanog
accord
manufactur
instruct
r
system
minneapoli
mn
usa
briefli
cell
fix
permeabil
methanol
aceton
c
min
nonspecif
bind
block
normal
hors
serum
antibodi
diluent
cell
incub
goat
antinanog
goat
antibodi
secondari
antibodi
alexa
fluor
antimous
molecular
probe
eugen
usa
incub
primari
antibodi
perform
overnight
c
wherea
incub
secondari
antibodi
h
room
temperatur
cell
examin
epifluoresc
microscopi
analyz
use
axiovis
compar
cycl
threshold
ddct
experi
perform
accord
manufactur
specif
total
reaction
volum
ml
experi
perform
three
replic
normal
pcr
result
use
hypoxanthin
phosphoribosyltransferas
housekeep
gene
perform
rel
quantif
rq
method
base
express
level
target
gene
versu
housekeep
gene
compar
differ
rtpcr
experi
set
experi
analyz
nanog
messeng
rna
express
level
msc
obtain
three
differ
cultur
condit
fbsmsc
condit
use
refer
sampl
analyz
multipot
capac
msc
cultur
condit
cultur
osteogen
adipogen
stemcel
technolog
vancouv
bc
canada
chondrogen
media
lonza
cologn
germani
day
accord
manufactur
instruct
briefli
cell
control
sampl
differenti
experi
seed
sixwel
plate
osteogenesi
adipogen
cultur
condit
respect
osteogen
differenti
demonstr
accumul
crystallin
hydroxyapatit
von
kossa
stain
adipogen
differenti
presenc
intracellular
lipid
vesicl
assess
oil
red
msc
chondrogen
differenti
obtain
previous
describ
differenti
evalu
alcian
blue
stain
identifi
presenc
hyaluron
acid
sialomucin
exclud
cytogenet
transform
ex
vivo
expans
msc
detach
cultiv
approxim
confluenc
reach
karyotyp
analysi
perform
cell
arrest
metaphas
incub
colcemid
invitrogen
corpor
grand
island
ny
usa
cell
maintain
hypoton
solut
moll
kcl
fix
methanolacet
acid
stain
giemsa
use
standard
laboratori
protocol
chromosom
analysi
least
cell
metaphas
analyz
use
macktyp
softwar
nikon
corpor
tokyo
japan
accord
intern
system
human
cytogenet
nomenclatur
exclud
potenti
tumorigen
induc
ex
vivo
expans
msc
perform
soft
agar
test
cell
cultur
condit
harvest
wash
seed
densiti
cellswel
plate
duplic
test
perform
use
agar
amem
hplihplfb
final
volumewel
ml
arrang
respect
base
surfac
cell
incub
day
c
presenc
co
incub
coloni
count
use
invert
microscop
primari
line
osteosarcoma
use
posit
control
sampl
whole
bm
healthi
donor
use
neg
control
microbiolog
control
sampl
hpl
media
cellular
supernat
test
bactalert
biom
erieux
durham
nc
usa
bacteriolog
laboratori
citi
scienc
health
turin
anna
hospit
perform
mycoplasma
detect
test
mycoplasma
detect
kit
convent
pcr
minerva
biolab
berlin
germani
use
aliquot
supernat
passag
expans
process
amount
growth
supplement
pure
hpl
ihpl
fb
briefli
mycoplasma
contamin
analyz
sampl
detect
semiquantit
pcr
reaction
posit
control
use
posit
control
dna
provid
kit
monitor
success
extract
procedur
use
intern
control
dna
venor
gem
neg
control
use
pcrgrade
water
statist
analys
perform
use
spss
ibm
chicago
il
usa
first
investig
whether
distribut
group
normal
distribut
use
shapirowilk
test
distribut
normal
use
nonparametr
friedman
test
compar
differ
group
consid
signific
differ
p
valu
two
batch
hpl
inactiv
ihpl
uninactiv
hpl
prepar
pool
six
pair
leukoreduc
bcpc
describ
averag
start
paramet
platelet
content
volum
leukocyt
content
bcpc
tabl
pi
treatment
keep
recommend
specif
treatment
platelet
intercept
larg
volum
process
system
transfus
use
compar
pair
untreat
unit
inactiv
bcpc
show
lower
platelet
count
result
addit
amotosalen
consequ
dilut
tabl
ii
multipl
transfer
step
includ
cad
incub
reduc
volum
platelet
yield
steril
test
neg
bcpc
unit
hpl
batch
test
endogen
adventiti
virus
one
sampl
result
posit
parvoviru
dna
hpl
ihpl
neg
nineteen
bm
sampl
collect
healthi
donor
year
age
age
rang
year
nine
year
age
rang
year
studi
carri
accord
helsinki
declar
adher
cell
clone
observ
sampl
day
cultur
adher
monolay
achiev
follow
day
hpl
ihplmsc
fbsmsc
reach
confluenc
day
plate
hplmsc
reach
mean
ae
standard
deviat
sd
cpd
ae
ae
ae
expand
amem
hpl
respect
cpd
hplmsc
significantli
greater
obtain
cultur
cell
amem
hpl
amem
fb
ae
use
control
p
base
chose
hpl
supplement
follow
experi
day
number
cell
significantli
greater
cell
plate
cellscm
low
densiti
plate
cellscm
high
densiti
independ
cellular
condit
mean
cfuf
number
ae
ae
ae
plate
densiti
cellscm
ae
ae
ae
plate
densiti
cellscm
respect
hplihplfb
msc
figur
although
absolut
number
coloni
count
three
cultur
condit
significantli
differ
observ
msc
cfuf
grown
hpl
ihpl
smaller
fb
cfuf
moreov
cfuf
hpl
ihplmsc
detach
analyz
cell
number
popul
smaller
denser
figur
b
reach
confluenc
faster
figur
e
cultur
fb
figur
c
f
also
observ
hplihplmsc
appear
smaller
easili
visibl
nucleoli
homogen
morpholog
characterist
figur
b
fbsmsc
fbsmsc
larger
show
polygon
morpholog
larg
jag
cytoplasm
figur
c
furthermor
hplihplmsc
detach
replat
h
cell
cultur
tend
reform
coloni
emit
promin
extens
morpholog
similar
pseudopodia
interestingli
creat
tridimension
structur
similar
embryoid
bodi
figur
e
observ
fbsmsc
figur
f
cellular
growth
analysi
show
cpd
third
passag
ae
ae
ae
mean
ae
sd
respect
hpl
ihpl
fbsmsc
hpl
ihplmsc
valu
show
strong
correl
p
signific
statist
differ
observ
cellular
growth
term
cpd
hpl
ihplmsc
compar
fbsmsc
p
p
respect
shown
figur
show
cpd
three
passag
bmmsc
cultur
condit
rel
mean
standard
deviat
first
three
passag
msc
analyz
passag
express
hematopoiet
surfac
antigen
membran
glycoprotein
also
call
use
stem
cell
marker
endoglin
cell
surfac
glycoprotein
first
passag
msc
isol
whole
bm
cultur
amem
hpl
ihpl
fb
antigen
express
wherea
show
high
express
cultur
condit
expans
time
msc
neg
hematopoiet
antigen
wherea
passag
express
high
percentag
statist
differ
observ
among
three
differ
media
tabl
iii
show
mean
percentag
antigen
express
analyz
passag
cell
cultur
three
differ
supplement
media
fluoresc
mean
posit
marker
third
passag
show
slight
increas
marker
slight
increas
hpl
ihplmsc
compar
fbsmsc
particular
hpl
ihpl
fbsmsc
show
hplihplmsc
detach
replat
tend
form
aggreg
cell
similar
structur
embryoid
bodi
seen
fbsmsc
therefor
analyz
embryon
stem
cell
marker
nanog
immunecytochem
techniqu
rtpcr
observ
posit
marker
protein
molecular
express
level
particular
observ
intens
nanog
nuclear
protein
express
higher
hplihplmsc
compar
fbsmsc
term
number
express
intens
shown
figur
cellular
structur
form
hpl
ihplmsc
fluoresc
concentr
nucleu
figur
b
figur
g
h
observ
isol
cell
nuclear
perinuclear
distribut
appear
figur
c
figur
count
posit
cell
found
hplmsc
ae
ae
ihplmsc
ae
ae
fbsmsc
ae
ae
respect
nanog
protein
express
data
confirm
rtpcr
analyz
sampl
observ
hpl
ihpl
induc
higher
nanog
gene
express
compar
fb
mean
rq
valu
ae
ae
ae
nanog
mean
rq
valu
ae
ae
ae
respect
hpl
ihpl
fbsmsc
right
panel
figur
b
show
repres
experi
msc
isol
expand
bm
sampl
three
differ
cellular
condit
friedman
test
protein
messeng
rna
express
show
signific
statist
differ
p
p
respect
msc
obtain
three
differ
condit
show
multipot
capac
sampl
differenti
osteoblast
adipocyt
chondrocyt
shown
figur
cell
expand
amem
hpl
ihpl
fb
show
chromosom
modif
tumorigen
transform
figur
passag
viabil
cell
cultur
condit
microbiolog
analys
includ
mycoplasma
test
neg
studi
show
hpl
safe
effici
msc
cultur
supplement
robust
msc
cultur
thu
offer
certain
advantag
compar
fb
especi
term
cell
growth
stem
mainten
moreov
repres
good
gmpcompliant
altern
anim
serum
msc
clinic
product
confirm
recent
data
report
literatur
hpl
prepar
perform
accord
blood
bank
procedur
high
standard
strongli
recommend
develop
hpl
batch
multipl
sourc
ie
differ
donor
make
hpl
virtual
standard
medium
supplement
growth
factor
concentr
interdonor
variabl
moreov
risk
transmiss
infect
agent
routin
test
test
avail
remain
hpl
qualiti
safeti
greatli
improv
done
photochem
treatment
amotosalem
uva
technolog
effici
vast
major
known
pathogen
might
also
prevent
transmiss
unknown
pathogen
intercept
technolog
routin
use
pi
platelet
plasma
clinic
use
inactiv
wide
spectrum
bacteria
virus
parasit
well
contamin
leukocyt
intercept
process
nucleic
acid
target
pi
technolog
howev
effect
prion
diseas
risk
prion
transmiss
treat
lysat
remain
even
though
precautionari
measur
donor
select
leucocyt
deplet
may
taken
obviat
problem
intercept
blood
system
class
iii
medic
devic
registr
requir
regulatori
review
preclin
clinic
data
system
routin
use
mani
blood
center
europ
middl
east
mani
countri
least
intercepttr
unit
transfus
worldwid
manufactur
support
extens
program
postmarket
surveil
hemovigil
studi
monitor
introduct
intercept
product
europ
studi
treat
platelet
unit
treat
plasma
unit
date
broad
patient
popul
intercept
platelet
plasma
safeti
profil
compar
convent
compon
efficaci
safeti
intercept
platelet
establish
trial
patient
moreov
recent
swiss
hemovigil
data
report
year
routin
transfus
inactiv
platelet
concentr
support
improv
safeti
profil
success
prevent
septic
transfus
reaction
introduct
pathogen
inactiv
techniqu
platelet
compon
intercepttr
platelet
receiv
addit
countryspecif
regulatori
approv
franc
germani
switzerland
new
applic
wide
use
techniqu
might
new
nich
blood
bank
latter
fact
could
use
method
provid
safer
product
clinic
cell
cultur
transplant
increas
safeti
patient
knowledg
data
report
pi
platelet
lysat
msc
expans
although
recent
studi
use
pih
compar
uninactiv
pathogenepih
show
pi
exert
neg
impact
human
islet
langerhan
msc
cell
cell
line
may
even
posit
effect
downregul
inflammatori
mediat
induc
dna
rna
strand
releas
damag
cell
sought
compar
simultan
hpl
ihpl
fb
exclud
abnorm
msc
isol
expans
caus
inactiv
literatur
wide
report
efficaci
psoralenuva
inactiv
use
blood
product
high
titer
ad
bacteria
envelop
nonenvelop
virus
protozoa
although
demonstr
inactiv
contamin
pathogen
beyond
scope
studi
howev
number
virus
requir
regulatori
author
routin
test
transfusion
center
batch
hpl
ihpl
show
pi
inactiv
virus
neg
almost
virus
test
show
good
select
donor
transfus
center
fundament
requir
safe
initi
blood
compon
posit
parvoviru
viru
transmit
asymptomat
blood
donor
recipi
blood
compon
high
rate
seroconvers
well
case
symptomat
ill
hypoplast
anemia
describ
patient
receiv
clot
factor
concentr
deriv
larg
plasma
pool
viru
rel
heatstabl
resist
treatment
solvent
deterg
dna
found
pcr
plasmaderiv
clot
factor
concentr
variou
manufactur
treat
use
differ
virusinactiv
method
variou
investig
clinic
evid
transfusiontransmit
infect
howev
infrequ
even
suscept
host
human
immunodefici
viruseinfect
hemophilia
patient
receiv
clot
factor
concentr
fact
posit
hpl
batch
neg
inactiv
show
also
found
pi
process
effici
safer
hand
intercept
treatment
hpl
result
loss
platelet
data
confirm
report
wagner
et
al
affect
cell
cultur
behavior
pi
treatment
may
trace
psoralen
may
contamin
ihpl
use
cad
level
residu
amotosalem
greatli
reduc
psoralen
concentr
platelet
approxim
mmoll
approxim
concentr
ihp
reduc
concentr
use
hpl
concentr
cell
cultur
although
test
presenc
psoralen
msc
expand
hpl
consid
psoralen
trace
msc
clinic
product
absolut
neglig
safe
conclus
light
fact
extracorpor
photochemotherapi
use
variant
cutan
tcell
lymphoma
graftversushost
diseas
system
sclerosi
solid
organ
transplant
reject
crohn
diseas
leukocyt
fraction
peripher
blood
expos
approxim
mmoll
photoactiv
reinfus
patient
without
collater
effect
howev
regard
transfusion
purpos
intercept
product
contraind
patient
histori
allerg
respons
psoralen
certif
analysi
msc
isol
expand
gmp
state
trace
psoralen
might
present
use
psoralenallerg
patient
found
hpl
ihpl
similar
characterist
advantag
term
cellular
growth
fb
interfer
mesenchym
phenotyp
modifi
mesenchym
marker
molecul
express
furthermor
hpl
ihpl
caus
chromosom
alter
karyotyp
modif
cell
expand
third
passag
interestingli
whole
bm
seed
hpl
ihpl
signific
differ
cfuf
number
observ
compar
fbsmsc
although
appear
denser
richer
term
cellscoloni
observ
confirm
number
detach
cell
passag
hpl
ihplmsc
show
higher
prolif
potenti
moreov
smaller
morpholog
homogen
fbsmsc
differ
cfuf
potenti
coloni
morpholog
may
repres
possibl
predict
cell
fate
function
recent
report
show
cfuf
analyz
combin
two
differ
piec
inform
diamet
densiti
properti
relat
affect
cell
prolifer
mobil
differenti
potenti
base
small
dens
coloni
observ
hpl
ihplmsc
repres
bmmsc
fraction
immatur
stem
cell
data
suggest
higher
clonal
expans
hplihplmsc
might
predict
greater
stem
fbsmsc
one
batch
hpl
ihpl
test
presenc
growth
factor
plateletderiv
growth
factor
fibroblast
growth
factor
observ
differ
term
quantiti
data
shown
maintain
growthpromot
effect
hpl
ihpl
probabl
due
growth
factor
specif
compound
releas
platelet
fraction
anoth
import
aspect
observ
hpl
ihpl
format
spheric
structur
similar
embryoid
bodi
togeth
pseudopodia
emiss
suggest
hplihplmsc
primit
stem
fbsmsc
shown
msc
isol
neonat
tissu
compar
adult
tissu
report
literatur
pseudopodia
emiss
may
suggest
trend
cell
migrat
consequ
repopul
damag
tissu
organ
potenti
implic
regen
medicin
entiti
occurr
higher
hplihplmsc
compar
fbsmsc
verifi
whether
morpholog
prolif
characterist
hplihplmsc
might
link
stem
fbsmsc
analyz
presenc
pluripotent
marker
nanog
alreadi
observ
msc
isol
neonat
tissu
amniot
fluid
key
transcript
factor
pluripot
selfrenew
phenotyp
undifferenti
embryon
stem
cell
nanog
homeodomain
protein
present
pluripot
human
cell
play
critic
role
regul
cell
fate
pluripot
inner
cell
mass
embryon
develop
maintain
pluripot
epiblast
prevent
differenti
primit
endoderm
nanog
thought
function
concert
factor
interestingli
spheroid
structur
observ
hpl
ihpl
seed
also
msc
detach
replac
passag
highli
posit
nanog
moreov
expans
hpl
ihpl
induc
select
primit
msc
compar
fb
although
hplihplmsc
exhibit
increas
cell
growth
term
cpd
characterist
attribut
higher
primit
stem
fbsmsc
demonstr
neither
hpl
ihpl
caus
vitro
tumorigen
mutat
karyotyp
modif
cell
expand
rd
step
data
accord
hpl
report
literatur
gmpcompliant
isol
expans
bmmsc
moreov
previous
report
plate
whole
bm
low
cellular
densiti
possibl
expand
high
number
msc
clinic
use
present
studi
show
independ
cultur
condit
number
cell
significantli
greater
whole
bm
cell
plate
low
densiti
compar
cell
plate
high
densiti
result
emphas
advantag
low
seed
densiti
whole
bm
isol
msc
largescal
use
use
hpl
altern
fb
isol
expand
msc
confirm
possibl
obtain
number
msc
clinic
dose
reduc
manufactur
time
limit
passag
reduc
start
volum
bm
final
demonstr
pi
treatment
modifi
characterist
hpl
made
safer
suitabl
msc
isol
expans
clinic
use
might
requir
gmp
msc
expans
